We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

333 hedge funds and large institutions have $1.33B invested in Recursion Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 68 funds opening new positions, 123 increasing their positions, 85 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 85

36% more call options, than puts

Call options by funds: $40.1M | Put options by funds: $29.5M

33% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 51

3% more funds holding

Funds holding: 322 → 333 (+11)

12.83% less ownership

Funds ownership: 75.87% → 63.04% (-13%)

16% less capital invested

Capital invested by funds: $1.58B → $1.33B (-$256M)

50% less funds holding in top 10

Funds holding in top 10: 8 → 4 (-4)

Holders
333
Holders Change
+11
Holders Change %
+3.42%
% of All Funds
4.05%
Holding in Top 10
4
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
68
Increased
123
Reduced
85
Closed
51
Calls
$40.1M
Puts
$29.5M
Net Calls
+$10.6M
Net Calls Change
-$11.1M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$36.7M
2
BlackRock
BlackRock
New York
+$35.3M
3
State Street
State Street
Massachusetts
+$35M
4
AIM
ARK Investment Management
Florida
+$18.7M
5
Citadel Advisors
Citadel Advisors
Florida
+$14.3M

Top Sellers

1
MIC
Mubadala Investment Company
United Arab Emirates
-$63.4M
2
NHAS
Novo Holdings A/S
Denmark
-$38.7M
3
NC
Nvidia Corp
California
-$37.6M
4
Morgan Stanley
Morgan Stanley
New York
-$8.09M
5
BPCE
Bank Pictet & Cie (Europe)
Germany
-$7.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
51
Invesco
Georgia
$2.15M +$535K +107,979 +26%
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$2.07M -$67.1K -13,557 -3%
LPL Financial
53
LPL Financial
California
$1.77M +$169K +34,084 +9%
Hudson Bay Capital Management
54
Hudson Bay Capital Management
Connecticut
$1.74M +$991K +200,000 +89%
Lazard Asset Management
55
Lazard Asset Management
New York
$1.72M -$372K -75,158 -15%
T. Rowe Price Associates
56
T. Rowe Price Associates
Maryland
$1.7M +$478K +96,479 +30%
Verition Fund Management
57
Verition Fund Management
Connecticut
$1.69M +$1.77M +358,169 +656%
CI
58
Carroll Investors
South Carolina
$1.66M +$40.8K +8,235 +2%
Mirae Asset Global ETFs Holdings
59
Mirae Asset Global ETFs Holdings
Hong Kong
$1.62M +$929K +187,504 +90%
ECM
60
ExodusPoint Capital Management
New York
$1.6M +$924K +186,564 +91%
SC
61
Sculptor Capital
New York
$1.58M +$1.73M +349,800 +966%
Legal & General Group
62
Legal & General Group
United Kingdom
$1.49M +$54.9K +11,092 +3%
AllianceBernstein
63
AllianceBernstein
Tennessee
$1.48M -$2.52K -508 -0.1%
PA
64
Profund Advisors
Maryland
$1.46M +$967K +195,207 +121%
California State Teachers Retirement System (CalSTRS)
65
California State Teachers Retirement System (CalSTRS)
California
$1.43M +$89.7K +18,103 +5%
Two Sigma Advisers
66
Two Sigma Advisers
New York
$1.28M -$2.48M -501,500 -62%
Deutsche Bank
67
Deutsche Bank
Germany
$1.22M +$138K +27,945 +10%
SC
68
Shay Capital
New York
$1.14M +$1.15M +231,530 +479%
HF
69
HRT Financial
New York
$1.05M +$1.27M +256,571 New
American Century Companies
70
American Century Companies
Missouri
$990K -$368K -74,213 -23%
Universal-Beteiligungs- und Servicegesellschaft
71
Universal-Beteiligungs- und Servicegesellschaft
Germany
$954K +$13.6K +2,753 +1%
HT
72
Headlands Technologies
Illinois
$947K +$210K +42,351 +22%
Marshall Wace
73
Marshall Wace
United Kingdom
$927K +$735K +148,350 +190%
SS
74
SBI Securities
Japan
$916K +$475K +95,810 +75%
AO
75
Allen Operations
New York
$890K – – –
1 2
3
4 5

RXRX Hedge Fund Activity: Q4 2025 in Review

333 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2025, worth a combined $1.33B — down 16% from $1.58B a quarter earlier.

Buyers outnumbered sellers: 68 funds opened new RXRX positions and 51 closed out — a net gain of 17 holders — while 123 added to existing stakes and 85 trimmed.

The largest buyer was Vanguard Group, adding an estimated $36.7M. The largest seller was Mubadala Investment Company, exiting entirely with an estimated $63.4M sold.

  • 333 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2025, up from 322 in Q3 2025.
  • Funds reported $1.33B of Recursion Pharmaceuticals stock for Q4 2025, down 16% quarter-over-quarter.
  • 68 funds opened new Recursion Pharmaceuticals positions in Q4 2025 and 51 closed out, a net change of +17 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2025 was Vanguard Group, an estimated $36.7M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2025 was Mubadala Investment Company, an estimated $63.4M sold.

Based on aggregated 13F filings for Q4 2025.